医学
肺癌
化疗
肿瘤科
疾病
癌症
内科学
入射(几何)
癌症研究
光学
物理
作者
Gordon Taylor Moffat,Tao Wang,Andrew Robinson
出处
期刊:Journal of The National Comprehensive Cancer Network
日期:2023-04-01
卷期号:21 (4): 336-339
标识
DOI:10.6004/jnccn.2022.7089
摘要
This report describes the management of small cell lung cancer (SCLC) transformation in a patient with untreated ALK-mutated advanced disease and a minimal smoking history, and a separate case of a de novo SCLC in a lifelong nonsmoker found to have a potentially targetable ERBB2 alteration. In the first case, chemotherapy followed by a targeted inhibitor was chosen due to the presence of the ALK rearrangement, as well as a somewhat discordant response to induction chemotherapy, suggesting possible progression of the ALK inhibitor-sensitive component. Molecular testing for the identification of driver mutations should be considered in patients with SCLC who have light/never smoking histories in order to help understand the incidence and ultimate optimal management strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI